258 related articles for article (PubMed ID: 24770886)
21. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.
Liu S; Yin L; Stroopinsky D; Rajabi H; Puissant A; Stegmaier K; Avigan D; Kharbanda S; Kufe D; Stone R
Blood; 2014 Jan; 123(5):734-42. PubMed ID: 24282218
[TBL] [Abstract][Full Text] [Related]
22. Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.
Hasegawa M; Sinha RK; Kumar M; Alam M; Yin L; Raina D; Kharbanda A; Panchamoorthy G; Gupta D; Singh H; Kharbanda S; Kufe D
Clin Cancer Res; 2015 May; 21(10):2338-47. PubMed ID: 25712682
[TBL] [Abstract][Full Text] [Related]
23. Hard antler extract inhibits invasion and epithelial-mesenchymal transition of triple-negative and Her-2
Xu G; Zhao H; Xu J; Zhang Y; Qi X; Shi A
J Ethnopharmacol; 2021 Apr; 269():113705. PubMed ID: 33346025
[TBL] [Abstract][Full Text] [Related]
24. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer.
Khodarev N; Ahmad R; Rajabi H; Pitroda S; Kufe T; McClary C; Joshi MD; MacDermed D; Weichselbaum R; Kufe D
Oncogene; 2010 Feb; 29(6):920-9. PubMed ID: 19915608
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
Yin L; Kosugi M; Kufe D
Blood; 2012 Jan; 119(3):810-6. PubMed ID: 22117045
[TBL] [Abstract][Full Text] [Related]
26. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
27. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.
Jin W; Liao X; Lv Y; Pang Z; Wang Y; Li Q; Liao Y; Ye Q; Chen G; Zhao K; Huang L
Cell Death Dis; 2017 Aug; 8(8):e2980. PubMed ID: 28796259
[TBL] [Abstract][Full Text] [Related]
28. Disruption of the NF-κB/IL-8 Signaling Axis by Sulconazole Inhibits Human Breast Cancer Stem Cell Formation.
Choi HS; Kim JH; Kim SL; Lee DS
Cells; 2019 Aug; 8(9):. PubMed ID: 31480284
[TBL] [Abstract][Full Text] [Related]
29. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.
Rajabi H; Alam M; Takahashi H; Kharbanda A; Guha M; Ahmad R; Kufe D
Oncogene; 2014 Mar; 33(13):1680-9. PubMed ID: 23584475
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.
Uchida Y; Raina D; Kharbanda S; Kufe D
Cancer Biol Ther; 2013 Feb; 14(2):127-34. PubMed ID: 23114713
[TBL] [Abstract][Full Text] [Related]
31. ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer.
Hinohara K; Kobayashi S; Kanauchi H; Shimizu S; Nishioka K; Tsuji E; Tada K; Umezawa K; Mori M; Ogawa T; Inoue J; Tojo A; Gotoh N
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6584-9. PubMed ID: 22492965
[TBL] [Abstract][Full Text] [Related]
32. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
33. ER81-shRNA inhibits growth of triple-negative human breast cancer cell line MDA-MB-231 in vivo and in vitro.
Chen Y; Zou H; Yang LY; Li Y; Wang L; Hao Y; Yang JL
Asian Pac J Cancer Prev; 2012; 13(5):2385-92. PubMed ID: 22901226
[TBL] [Abstract][Full Text] [Related]
34. MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
Yamamoto M; Jin C; Hata T; Yasumizu Y; Zhang Y; Hong D; Maeda T; Miyo M; Hiraki M; Suzuki Y; Hinohara K; Rajabi H; Kufe D
Cancer Res; 2019 Apr; 79(8):2031-2041. PubMed ID: 30824588
[TBL] [Abstract][Full Text] [Related]
35. Mammospheres of hormonal receptor positive breast cancer diverge to triple-negative phenotype.
Laranjo M; Carvalho MJ; Costa T; Alves A; Oliveira RC; Casalta-Lopes J; Cordeiro P; Botas F; Abrantes AM; Paiva A; Oliveira C; Botelho MF
Breast; 2018 Apr; 38():22-29. PubMed ID: 29182983
[TBL] [Abstract][Full Text] [Related]
36. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor.
Ahmad R; Raina D; Joshi MD; Kawano T; Ren J; Kharbanda S; Kufe D
Cancer Res; 2009 Sep; 69(17):7013-21. PubMed ID: 19706766
[TBL] [Abstract][Full Text] [Related]
37. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
[TBL] [Abstract][Full Text] [Related]
38. Small molecule 1'-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway.
Wang J; Zhang L; Chen G; Zhang J; Li Z; Lu W; Liu M; Pang X
Breast Cancer Res Treat; 2014 Nov; 148(2):279-89. PubMed ID: 25301089
[TBL] [Abstract][Full Text] [Related]
39. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
[TBL] [Abstract][Full Text] [Related]
40. MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 β1,6-N-acetylglucosaminyltransferase and β-galactoside α2,3-sialyltransferase.
Solatycka A; Owczarek T; Piller F; Piller V; Pula B; Wojciech L; Podhorska-Okolow M; Dziegiel P; Ugorski M
Glycobiology; 2012 Aug; 22(8):1042-54. PubMed ID: 22534569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
